Sodium–glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients

Recent major clinical trials of the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes have shown that they reduce three‐point major adverse cardiovascular events, cardiovascular death, hospitalization for heart failure (HF) and a composite renal outcome. These...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashiwagi, Atsunori, Araki, Shinchi, Maegawa, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779279/
https://www.ncbi.nlm.nih.gov/pubmed/32563214
http://dx.doi.org/10.1111/jdi.13329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779279/
https://www.ncbi.nlm.nih.gov/pubmed/32563214
http://dx.doi.org/10.1111/jdi.13329

Ejemplares similares